Delivery Order SPE2DB20D9759-SPE2DB24FD5NA

Award Date 9/26/24
Potential Completion Date 10/18/24
Potential Value $1.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $1,270.95, is for the delivery of SKYLA 13.5 MG SYSTEMS, a pharmaceutical product, with a performance period through May 13, 2024. The contract is part of DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA, valued at up to $499,999,999, under the SPE2DB...
This is a $1,822.36 firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a for-profit woman-owned small business. The delivery order is for the supply of a pharmaceutical product called SKYLA 13.5 MG SYSTEMS. DMS Pharmaceutical Group holds a broader indefinite delivery contract with DLA to provide various medical supplies and pharmaceutical items to military treatment facilities worldwide. This specific delivery order is not associated...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,822.36 contract is for the delivery of SKYLA 13.5 MG SYSTEMS, a specialized pharmaceutical product, with a performance period through March 16, 2023. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract has a completion date of February 13, 2024 and a potential value of $7,061.25. It is for the delivery of SKYLA 13.5 MG SYSTEMS, a pharmaceutical product, to support the medical needs of the Department of Defense. DMS Pharmaceutical Group Inc. is a leading pharmaceutical wholesaler that provides a wide range of brand and generic...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $2,353.75, is for the supply of the pharmaceutical product SKYLA 13.5 MG SYSTEMS. The award is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA under the SPE2DB program, valued at up to $499,999,999 and running through...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business, for the provision of the SKYLA 13.5 MG SYSTEMS pharmaceutical product. The contract has a firm fixed price pricing type and a potential value of $1,412.25. The period of performance runs through February 29, 2024. This award is associated with DMS Pharmaceutical Group's larger indefinite delivery contract 4600082013 under the DLA's SPE2DB program,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $23,537.50 firm fixed-price delivery order is for SKYLA 13.5 MG SYSTEMS and has an ultimate completion date of October 9, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue...
The Defense Logistics Agency awarded a firm fixed price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide 4563401429 - SKYLA 13.5 MG SYSTEMS. The $3,295.25 delivery order has a completion date of February 5, 2024. DMS Pharmaceutical Group is a leading pharmaceutical wholesaler that holds various indefinite delivery contracts with the Defense Logistics Agency to supply pharmaceuticals and medical products to military treatment facilities globally. This...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $4,236.75, is for the delivery of Skyla 13.5 mg systems, a specialized pharmaceutical product. DMS Pharmaceutical Group holds a $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to issue firm...
The Defense Logistics Agency (DLA) has awarded a $2,824.56 firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of SKYLA 13.5 MG SYSTEMS and is valid through October 18, 2024. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue firm fixed-price...
  • SPE2DB20D9759
    Indefinite Delivery Contract
  • SPE2DB20D9759-SPE2DB24FD5NA
    Delivery Order

This is a firm fixed-price delivery order contract awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA) on September 26, 2024. The contract, which has a ceiling value of $1,412.25, is for the delivery of SKYLA 13.5 MG SYSTEMS and has an ultimate completion date of October 18, 2024. The contract is not set aside for any specific small business program.

This delivery order is part of a larger indefinite delivery contract (IDC) that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program, which has a potential value of up to $499,999,999 and runs through December 31, 2025. Under this IDC, DMS Pharmaceutical Group provides a comprehensive range of pharmaceutical items, from common medications to specialized drugs and medical supplies, to support the diverse medical needs of military personnel and their dependents across various Department of Defense healthcare facilities.

Generated 12/26/24, 9:10 AM